Updated:
SomaLogic
SomaLogic is a company based in Boulder, Colorado, founded in 1999. It provides high-throughput proteomics services to academic institutions, pharmaceuticals,...
SomaLogic
SomaLogic is a company based in Boulder, Colorado, founded in 1999. It provides high-throughput proteomics services to academic institutions, pharmaceuticals, and biotechnology companies. SomaLogic offers the SomaScan Assay and was acquired by Illumina in January 2026 for $350M–$425M.
General information
Firm type
Biotechnology
Year founded
2000
Location
Region
Europe
Country
United States
City
Boulder
Corporate office
Boulder, CO, United States
Additional offices
Basel, Switzerland
Principals
Adam Taich
Chief Executive Officer
Larry Gold
Founder
Sector focus
Frequently asked questions
Who runs investment decisions at SomaLogic?
Adam Taich has been CEO since 2022, succeeding founder Larry Gold. The firm is a publicly traded biotechnology company, so investment decisions — such as capital allocation and R&D spending — are made by management and approved by its board of directors. No family office or wealth management structure exists.
How does SomaLogic source proprietary deal flow?
SomaLogic generates revenue through partnerships and service agreements with pharmaceutical companies, academic institutions, and biobanks. Its proprietary SomaScan platform serves as the core offering, and the firm actively pursues collaborations to integrate the assay into large-scale clinical trials and population-health studies.
Is SomaLogic structured as a single family office or does it operate more like a venture firm?
Neither. SomaLogic is a publicly traded biotechnology company (NASDAQ: SLGC) focused on proteomics. It is not a family office, asset manager, or venture capital firm. The company operates as a diagnostics and data-services platform.
Does SomaLogic participate in fund commitments or only direct deals?
SomaLogic does not participate in fund commitments or direct investments. Its business model is based on licensing and service fees from its proteomics platform. The firm is not an investment vehicle.
What investment stages does SomaLogic typically target?
SomaLogic does not target investment stages. The company's focus is on R&D and commercialization of its SomaScan assay. It engages with partners at various stages of drug development, from preclinical research to Phase III trials.
Which sectors does SomaLogic explicitly avoid?
SomaLogic's platform is broadly applicable across therapeutic areas, but publicly disclosed partnerships focus on cardiometabolic diseases, oncology, and neuroscience. No explicit sector avoidance is documented.
Where does the underlying wealth come from?
SomaLogic is a publicly traded company, not a family office or trust. Its capital comes from public equity markets, including funds raised via its SPAC merger in 2021. No individual or family wealth is managed through the entity.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: